MORE than 80% of clinical trial data submitted to support new drug registrations in China have been revealed as fraudulent or substandard by the country's own drug regulator, the State Food and Drug Administration, according to a report in The BMJ.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 07 Oct 16
To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Oct 16
